roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche reveals first data with
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche reveals first data with](https://pharmaphorum.com/sites/default/files/styles/x_large/public/2023-10/Roche_logo.jpg?itok=-fpSgFk6)
![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche reveals first data with](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/Structure%20support.jpg?VersionId=IqhUtEq847RmKGNDTcDf7PW7BmOaxUZU)
![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche reveals first data with](https://medcitynews.com/wp-content/uploads/sites/7/2021/03/GettyImages-103032608-600x399.jpg)
![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche reveals first data with](https://assets.bwbx.io/images/users/iqjWHBFdfxIU/ii.wuRX.juj8/v0/1200x800.jpg)























